Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Accumulated Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Accumulated Expenses for 13 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 79.4% to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.6 million through Dec 2025, up 79.4% year-over-year, with the annual reading at $12.6 million for FY2025, 79.4% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $12.6 million at Theravance Biopharma, up from $10.3 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $12.8 million in Q4 2021, with the low at $3.9 million in Q2 2021.
  • Average Accumulated Expenses over 5 years is $7.5 million, with a median of $7.0 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses plummeted 85.42% in 2021, then soared 79.4% in 2025.
  • Over 5 years, Accumulated Expenses stood at $12.8 million in 2021, then decreased by 19.4% to $10.3 million in 2022, then crashed by 37.53% to $6.4 million in 2023, then rose by 8.94% to $7.0 million in 2024, then surged by 79.4% to $12.6 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $12.6 million, $10.3 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.